He writes: “We continue to believe lead asset, antibiotic Xerava, has substantial potential utility in complicated intra-abdominal infection (cIAI), with an upcoming August 27, 2018, PDUFA data as a key potential positive catalyst for TTPH shares.” So far the signs are positive, as Xer...
Regulatory Approvals:Approval from regulatory bodies, such as the Food and Drug Administration (FDA) for pharmaceutical companies, can significantly impact stock prices. Positive regulatory news can drive prices up, while delays or rejections can lead to sharp price declines. Day traders closely monito...
Helping,analysts atJefferies(NYSE:JEF) recently initiated a Buy rating on the stock with a price target of $37. The firm argues that the company is on the brink of commercialization with its upcoming U.S. decisions on axatilimab, and revumenib for the treatment of acute myeloid leukemia....
Success Possibilities: If its drugs receive regulatory approval and commercial success, BridgeBio’s shares could continue their upward trajectory. Market forecasts for today indicate a stable opening, with a slight adjustment to $27.82 in pre-market. 3. Intel Corporation (NASDAQ: INTC) Overview: Se...
Company also has 18 ANDA approvals from the US FDA with 46 ANDAs in the pipeline which will drive US business.April 3, 2020 04:03 Top Picks Bharti Airtel CMP: `421 Target Price: `492 Upside: 16.8% Telecom operators have increased tariffs by ~35% in Nov’19 and there is possibility ...
News and Catalysts: Stay informed about the latest news and upcoming catalysts related to the company. News such as positive clinical trial results, regulatory approvals, or collaborations can significantly impact a biotech stock’s performance. Keep an eye on upcoming events that may act as cataly...
Neurocrine's second drug is a treatment for endometriosis called Orilissa. This drug just recently won the thumbs up from the FDA in the third quarter of 2018 and holds blockbuster potential. Neurocrine has partnered with pharma giantAbbVieto commercialize the drug, and it pulls in a20% royalty...
But White pointed out that in late March, Dynavax said the European Medicines Agency accepted the company's application for Heplisav-B, which has a targeted approval in the first quarter of 2021. So White remains firm on this year's goals and sees big things down the road."We main...
All primary and secondary endpoints were met for this study and results were consistent with findings from the first Phase 3 study. Results support Botox Cosmetic as a potential treatment option for moderate to severe platysma prominence and data will be included as part of an upcoming FDA ...
year. A number of its drugs have gained approval from the U.S. Food and Drug Administration (FDA) this year, and it hopes to win approvals on others later this year. A total of 66 hedge funds in the VIP basket hold Celgene’s stock and 44 of those hold it as one of their top ...